Navigation Links
Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients
Date:12/7/2008

llennium Pharmaceuticals, Inc. and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S., Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. VELCADE is approved in more than 87 countries worldwide.

Important Safety Information

In the U.S., VELCADE is indicated for the treatment of patients with multiple myeloma. VELCADE also is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension throughout therapy, cardiac and pulmonary disorders, reversible posterior leukoencephalopathy syndrome, gastrointestinal adverse events, thrombocytopenia, neutropenia, tumor lysis syndrome and hepatic events. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Nursing mothers are advised not to breastfeed while receiving VELCADE. Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and new onset of decreased left ventricular ejection fraction has been reported, including reports in patients with no risk factors for decreased left ventricular ejection fraction. There have been reports of acute diffuse infiltrative pulmonary disease of unknown etiology such as pneumonitis, interstitial pneumonia, lung infiltration and Acute Respiratory Distress Syn
'/>"/>

SOURCE Millennium: The Takeda Oncology Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Boston Scientific Corporation ... in the Barclays 2015 Annual Healthcare Conference on March ... Dan Brennan , executive vice president and ... president, Investor Relations, will participate in a 25-minute question ... analyst at approximately 1:05 p.m. ET. Following a 5-minute ...
(Date:2/27/2015)... 27, 2015  In recognition of Rare Disease Day ... global bleeding disorders community, CSL Behring announced ... (IUs) of protein therapies to the World Federation of ... which has worked to improve the lives of people ... supports the WFH,s Global Alliance for Progress (GAP) Program ...
(Date:2/27/2015)... 2015  Organovo Holdings, Inc. (NYSE MKT: ONVO) ... breakthrough 3D bioprinting technology, announced today that ... will present live at VirtualInvestorConferences.com on March 5th. ... us for this Company update," said Mr. Murphy. ... launch of the exVive3D Liver, Bioprinted Human Tissue, ...
Breaking Medicine Technology:Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 2CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4
... , PALO ALTO, Calif., Dec. 2 Varian, Inc. (Nasdaq: ... with the U.S. Securities and Exchange Commission its Annual Report on ... This Annual Report may be accessed through the Company,s web site ... on "10-K" in the table shown. Stockholders may receive a ...
... , NEW YORK, Dec. 2 ... is available in its catalogue: , Pharmaceutical ... http://www.reportlinker.com/p0164248/Pharmaceutical-Contract-Manufacturing---Global-Market-Trends.html , Global pharma ... competition in generic markets, rising cost of new product ...
Cached Medicine Technology:Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 2Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 3Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 4Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 5
(Date:2/28/2015)... Malaysia (PRWEB) February 28, 2015 The ... all across Malaysia into one platform and gears towards ... , A series of group talks in smaller ... like Nation Building, Education, Personal Development, Leadership, Entrepreneurship, Healthcare, ... and raise awareness of Malaysian youths. , ...
(Date:2/28/2015)... Gerald “Solutionman” Haman surveyed over 10,000 people ... innovative thinking. “The #1 block was lack of ... reports Haman, who created the Thinkubator Innovation Studio in ... that they did not have enough time for innovative ... stimulate innovation. , Solutionman’s monthly “Accelerating Innovation Training” workshops ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 March—also ... good time to remind ourselves and others that ... say Atlantic NeuroSurgical Specialists (ANS). , Concussions are ... account for 75% of TBIs. There are 1.6-3.8 ... may sound benign, but it is a brain ...
(Date:2/28/2015)... A study out of the University of ... for the treatment of a hereditary ocular condition that ... by Dr. Robert MacLaren, professor of ophthalmology at the ... Journal on January 16, 2014 , the study treated ... that mostly affects men and leads to the degeneration ...
(Date:2/28/2015)... 28, 2015 National Sales ... sales, marketing and supply chain management for consumer ... is bringing its award winning solutions for thinning-damaged ... products are specifically created to combat thinning-damaged hair. ... is committed to marrying science with nature to ...
Breaking Medicine News(10 mins):Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 2Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 3Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3
... 12 InfuSystem Holdings, Inc.,(OTC Bulletin Board: INHI; ... and associated clinical services, today announced,financial results and ... of,2008., Mr. Steve Watkins, chief executive officer, ... first full quarter of operations as a stand-alone,public ...
... Medical Association (AVMA) has revised its policy on ... additional guidance,for managing pain associated with these procedures. ... not dictate that practitioners use any,particular method of ... recommendations for consideration by practitioners when they work,with ...
... The American Veterinary,Medical Association (AVMA) has reinforced its ... and other equines by approving a,new policy on the ... the AVMA Executive Board on April 12, 2008,states that ... opposes the,use of double-deck trailers to transport equines. The ...
... Regulatory Authority Over Tobacco, WASHINGTON, May 9 ... country, today announces their,support of H.R. 1108, "The ... gives FDA regulatory authority over tobacco products., ... this year.,H.R. 1108 has broad bi-partisan support and ...
... N.H., May 12 Atrium Medical Corporation ... and precautionary recall of,selected lots of HYDRAGLIDE(TM) ... Atrium heparin-coated Hydraglide Thoracic,Catheters were manufactured with ... chondroitin sulfate (OSCS). The patient risk associated,with ...
... community observes,the destructive aftermath of the world,s second ... mounting frustration over getting humanitarian aid,for cyclone victims, ... been proactive-and more importantly, successful-in initiating,medical care at ... 100,000 people,are assumed dead. AMIMA has funded the ...
Cached Medicine News:Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 2Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 3Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 4Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 5Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 6Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 7Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 8Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 9Health News:Revised AVMA Policy on Castrating and Dehorning Cattle Provides Additional Guidance for Managing Pain 2Health News:AVMA Opposes Use of Double-Deck Trailers for Transporting Horses and Other Equines 2Health News:Atrium Initiates Voluntary Recall Action Regarding HYDRAGLIDE(TM) Brand Heparin-Coated Thoracic Drainage Catheters Used for Autotransfusion During Cardiopulmonary Bypass Surgery 2Health News:Alumni Myanmar Institutes of Medicine Association (AMIMA) Races Time to Help Cyclone Victims 2
... Vision, Quality of Vision and Contrast ... target illumination and glare luminance levels ... Day/Night testing with/without glare and background ... all ANSI standards. All Light Levels ...
Contrast Sensitivity is Recognized as a Valuable Tool for Measuring Functional Vision Loss Caused by Early Eye Disease. Distance Test S.W.C.T. 201: Size 27in x 37 in (68.58cm x 93.98cm),Can be Wal...
Vectograms are the standard for vision training. They are available in fixed or variable,styles to accommodate unlimited base-in and base-out training. Each vectogram,includes one pair,of standard 3-...
Adult: Letter Monocular Acuity, Binocular Astigmatism, Acuity Balance, Supression, Binocular Acuity, Fixation Desparity, Muscle Balance, Stereopsis...
Medicine Products: